African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2256


Antimalarial drugs: Mode of action and status of resistance

Muheet Alam Saifi1*, Tanveer Beg2, Abdul Halim Harrath1, Fahad Suleman Hamad Altayalan1 and Saleh Al Quraishy1
1Department of Zoology, College of Science, King Saud University, Riyadh-11451, Kingdom of Saudi Arabia. 2Department of Biology, College of Science, Jazan University, Jazan, Kingdom of Saudi Arabia.
Email: [email protected]

  •  Accepted: 14 December 2012
  •  Published: 08 February 2013


Malaria is a major global health problem, with an estimated 300 to 500 million clinical cases occurring annually. Malaria remains one of the leading causes of disease and death in the tropics, mainly of children under 5 years of age. The most prevalent and dangerous type of malaria is caused by Plasmodium falciparum. P. vivax is a common cause of malaria in Latin America, Asia, and Oceania, but not Africa. P. malariae and P. ovale are much less common. Antimalarials are used in three different ways: prophylaxis, treatment of falciparum malaria, and treatment of non-falciparum malaria. Prophylactic antimalarials are used almost exclusively by travelers from developed countries who are visiting malaria-endemic countries. The antimalarials in common use come from the following classes of compounds: the quinolines (chloroquine, quinine, mefloquine, amodiaquine, primaquine), the antifolates (pyrimethamine, proguanil and sulfadoxine), the artemisinin derivatives (artemisinin, artesunate, artemether, arteether) and hydroxynaphthaquinones (atovaquine).


Key words: Malaria, resistance, antimalarial drugs, plasmodium.